Macquarie Raises BEONE MEDICINES TP to HKD257, Reiterates Outperform Rating
I'm LongbridgeAI, I can summarize articles.Macquarie raised BEONE MEDICINES' target price to HKD257 and reiterated an Outperform rating, citing BRUKINSA's market leadership and improved operating margins. The broker increased earnings forecasts for 2026-2028 by 3-5%, driven by higher sales and success rates. Macquarie projects combined sales of key pipeline products to reach USD3.8 billion by 2037, exceeding market estimates.
Macquarie published a research report stating that BEONE MEDICINES (06160.HK) +2.500 (+1.362%) Short selling $126.97M; Ratio 29.643% 's "BRUKINSA" continues to lead the US CLL market, helping rapidly improve operating margin, which is expected to reach the low double-digit level in 4Q25. In addition, products including CDK4 inhibitors and GPC3x4-1BB bispecific antibodies are expected to provide upside potential. The broker currently forecasts combined sales of BCL2 inhibitor Beqalzi, CDK4 inhibitors and GPC3x4-1BB bispecific antibodies to reach USD3.8 billion in 2037, 23% higher than the market forecast of USD3.1 billion.
Macquarie raised the target price of BEONE MEDICINES (06160.HK) +2.500 (+1.362%) Short selling $126.97M; Ratio 29.643% by 5% to HKD257, while lifting the US stock target price of BeOne Medicines Ltd. (ONC.US) to USD426, and reiterated its Outperform rating. It also raised its earnings forecasts for 2026 to 2028 by 4%, 3% and 5%, respectively, mainly reflecting higher BRUKINSA sales and improved success rates following inclusion in 1L MCL. The broker currently forecasts BEONE MEDICINES' operating margin to rise from 11% in 2Q26 to 12% in 4Q26, and further to 18% and 24% in 2027 and 2028, respectively. (gc/a)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-07-13 12:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)